SymBio Pharmaceuticals

SymBio Pharmaceuticals, founded in 2005 in Minato, Tokyo, in-licenses medicines for Japan and runs the domestic trials for approval. It won Japanese approval for bendamustine (Treakisym) in relapsed indolent lymphoma, mantle cell lymphoma and later first-line settings, and is developing brincidofovir for adenovirus infection after stem cell transplant. Its phase 3 trials are registered on ClinicalTrials.gov under SymBio as lead sponsor.